A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian cancer.
A phase 3 trial found that relacorilant, when combined with chemotherapy drug nab-paclitaxel, improved progression free survival compared to the chemotherapy alone, according to a March 31 news release from the drugmaker.
Patients receiving relacorilant had a 30% lower risk of disease progression, with a median progression free survival of 6.5 months compared to 5.5 months for those on chemotherapy alone.
Corcept Therapeutics plans to submit a new drug application with the FDA in the third quarter of 2025, with full trial results expected to be presented at a medical conference later this year.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
